Drug Information

General Information
Drug ID
DR00283
Drug Name
Dopamine
Synonyms
(3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol; A-(3,4-Dihydroxyphenyl)-b-aminoethane; ASL 279; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamin; Dopamina; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine (USAN)(*hydrochloride*); Dopamine [INN:BAN]; Dopaminum; Dopaminum [INN-Latin]; Dophamine; Hydroxytyramin; Hydroxytyramine; IP 498; Intropin; Intropin [*hydrochloride*]; KW-3-060; L-DOPAMINE; LDP; M-Hydroxytyramine hydrochloride; Medopa (TN); Oxytyramine; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; Revimine
Drug Type
Small molecular drug
Indication Parkinson's Disease [ICD11:8A00.0] Approved [1]
Therapeutic Class
Cardiotonic Agents
Structure
3D MOL 2D MOL
Formula
C8H11NO2
Canonical SMILES
C1=CC(=C(C=C1CCN)O)O
InChI
InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
InChIKey
VYFYYTLLBUKUHU-UHFFFAOYSA-N
CAS Number
CAS 51-61-6
Pharmaceutical Properties Molecular Weight 153.18 Topological Polar Surface Area 66.5
Heavy Atom Count 11 Rotatable Bond Count 2
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 3
XLogP
-1
PubChem CID
681
PubChem SID
11111282 ,11335955 ,11361194 ,11363906 ,11364800 ,11364894 ,11366468 ,11367362 ,11367456 ,11369030 ,11369924 ,11370018 ,11371252 ,11372964 ,11373057 ,11374268 ,11375524 ,11375618 ,11377192 ,11378091 ,11378187 ,11462166 ,11484941 ,11488839 ,11490222 ,11492340 ,11494826 ,11534314 ,15170929 ,24439043 ,26612791 ,26719173 ,26750067 ,26753786 ,26753787 ,3133522 ,37024415 ,4396596 ,444583 ,46506043 ,47213204 ,6517 ,7888623 ,794678 ,7979122 ,8026221 ,8145174 ,8150742 ,840958 ,841083
ChEBI ID
ChEBI:18243
TTD Drug ID
D0T7OW
DT(s) Transporting This Drug 1-Oct Transporter Info Organic cation transporter 1 Substrate [2]
2-Oct Transporter Info Organic cation transporter 2 Substrate [3]
DAT1 Transporter Info Sodium-dependent dopamine transporter Substrate [4]
SV2C Transporter Info Synaptic vesicle glycoprotein 2C Substrate [5]
VMAT1 Transporter Info Vesicular amine transporter 1 Substrate [6]
VMAT2 Transporter Info Vesicular amine transporter 2 Substrate [6]
Drug-Transporter Activity Data
Drug-Transporter Activity Data 2-Oct Transporter Info Km =330 microM Human embryonic kidney cells (HEK293)-OCT2 [7]
2-Oct Transporter Info Km =1400 microM Human embryonic kidney cells (HEK293)-OCT2 [3]
2-Oct Transporter Info Km =390 microM Oocytes-OCT2 [7]
References
1 Dopamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
3 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
4 Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
5 Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
6 SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
7 Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.